Weather forecast

Moderna (MRNA) stock forecast

Partly cloudy

Hold

Score 48/100 · Confidence 55%

A mixed forecast — patience tends to pay here.

Weighed fromlive price action

Why this call

Strong Momentum Clashes With Weak Fundamentals

Strong recent buying pressure continues to be a major factor for the stock.

Declining revenue and a lack of profits create fundamental headwinds.

The 52-week high of $68 could act as a price ceiling.

Where it's headed

Moderna price targets

As of Jun 19, 2026, Tickerday rates Moderna (MRNA) a Hold, score 48/100, with 55% confidence. Each target is measured from $63.98, the price that day.

Next week

$63

−1.5% from $63.98

The stock's recent powerful rally might pause for a breather in the very short term after hitting new highs.

Next month

$65

+1.6% from $63.98

Strong momentum could continue to battle against weak underlying business results over the next month.

Next year

$50

−21.9% from $63.98

The stock's current price seems high given the company's declining revenue and significant losses, which will likely weigh on performance.

Share this forecastXRedditWhatsApp

Under the hood

What the engine weighed

Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.

48Overall score
Valuation
25

The company's lack of profits makes it difficult to value with traditional metrics.

Growth
15

Revenue has declined significantly over the past year as vaccine sales have slowed.

Profitability
10

The company is currently unprofitable on a net basis, with deeply negative margins.

Momentum
95

The stock has shown exceptionally strong price performance, trading near its 52-week high.

Fin. health
90

The balance sheet is very strong, with a low debt-to-equity ratio.

Sentiment
50

Market sentiment appears neutral in the absence of major recent news.

Key numbers

as of Jun 19, 2026

Size and price

Growth and profit

Risk and payout

The argument

Both sides of the sky

Every call has a case against it. Here's the honest version of both.

The bull case

  • The stock has shown very strong price momentum, more than doubling from its 52-week low.
  • With a very low debt-to-equity ratio of 0.09, the company has a fortress-like balance sheet to fund future research.
  • Despite overall losses, the company maintains a healthy gross margin of 35% on its products.

The bear case

  • Revenue has fallen by 30% over the last year, a significant headwind as vaccine sales have slowed.
  • The company is currently not profitable, reporting significant losses per share.
  • Future growth is heavily dependent on the success of its drug pipeline, which is inherently uncertain.

FAQ

Good questions

Tickerday's read of Moderna as of Jun 19, 2026: educational analysis, the same for everyone, not financial advice.

Most tools hand you the data.
Tickerday hands you the answer.

Now try yours

What about your stocks?

You just read Moderna. Type a company you own and get its call, and the why, in seconds. First one free, no account needed.

SearchApple

The receipts

Called it. Then it happened.

Real calls from the Tickerday engine, each one graded against the real price a month later.

Palantir Technologies Inc.

+52.3%

✓Called it

We said Buy at $122.33 on Jul 30. A month later the price was $186.29.

Graded Aug 28 at the closing price

Today's prices

Weather alerts

We'll watch the weather.You enjoy the day.

Save a stock to your Almanac. We'll track its forecast and let you know when the outlook changes.

Your Almanac

Watching 4 stocks

MRNA

Moderna

Hold

AAPL

Apple

Buy

MSFT

Microsoft

Buy

TSLA

Tesla

Sell

9:41

Thursday, October 16

9:41

Nothing to chase. Nothing to refresh.

Sunny under an umbrella

One blind call costs more
than a year of Tickerday.

Pricing

Start free, right here

Your first analysis is free, no account needed. Tickerday+ takes it from there.

Tickerday+

Pro

Built for fast clarity.

  • Clear buy / hold / sell-style insights
  • Key risks and opportunities
  • Focused market analysis
  • 40 priority credits every month
$9/mo

Billed monthly · ≈ $0.30/day

Tickerday+

Most popular

Premium

The full why, explained.

  • Expanded analysis & learning depth
  • Interactive explanations & breakdowns
  • Tap to understand key metrics & terms
  • 100 priority credits every month
$228 (was)$169/yrSAVE 26%

Billed yearly · ≈ $14.08/mo≈ $0.46/day

Cancel anytime.

Sunny, Tickerday's mascot, fast asleep under the stars

Get the full picture

That took thirty seconds. Now imagine every stock you own.

You just understood MRNA without reading a single chart. The Tickerday app does this for your whole watchlist — today's read whenever you want it, the full thesis, bull and bear scenarios with their odds — and wakes you the moment the weather turns.

One plain answer for every stock — Buy, Hold, or Sell

The full picture in seconds — thesis, targets & scenarios

Sleep easy — we watch the market and wake you if it turns

Free to download the day it lands — the web desk is open now

More forecasts

Head to head

More lists